Tizanidne Hydrochloride Capsule
Product Images NDC 63629-8873

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tizanidne Hydrochloride (NDC 63629-8873). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl636298873)

Label for Tizanidine Hydrochloride Capsules, 6 mg, manufactured by Bryant Ranch Prepack. The label states the product NDC as 63629-8873-1 and indicates a package size of 150 capsules. It includes storage instructions, a barcode, and the BRP Pharmaceuticals logo.*

FDA Label Image

Tiz01 (Tiz01)

Chemical structure diagram of tizanidine hydrochloride, showing its molecular arrangement with chlorine, nitrogen, sulfur atoms, and hydrochloride moiety. The image depicts the 2D structural formula of the active ingredient tizanidine hydrochloride.*

FDA Label Image

Tiz02 (Tiz02)

A line graph showing plasma Tizanidine concentration (ng/mL) over time (hours from dosing) for 4 different conditions: 2 x 4 mg Tizanidine tablets with food, 2 x 4 mg Tizanidine tablets without food, 2 x 4 mg Tizanidine capsules with food, and 2 x 4 mg Tizanidine capsules without food. The graph displays concentration peaking within a few hours post-dosing and declining afterward up to 24 hours.*

FDA Label Image

Tiz03 (Tiz03)

A line graph depicting the improvement in Ashworth Score over time (hours post-dose) for three groups: 16 mg tizanidine, 8 mg tizanidine, and placebo. The y-axis represents improvement scores, and the x-axis shows hours from 0 to 6. 16 mg shows the greatest improvement, followed by 8 mg, with placebo showing minimal change.*

FDA Label Image

Tiz04 (Tiz04)

A line graph depicting improvement in Ashworth Score over time with two treatments: tizanidine (mean dose 28.8 mg) and placebo. The x-axis shows three time points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (last observation carried forward). The y-axis measures improvement, ranging from -6 to 2, with negative values indicating improvement. Tizanidine generally shows greater improvement than placebo at all observed time points, with error bars representing variability.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.